Licensing Developmental-Support Software in India: An April 2026 Case Study Assessed Against CDSCO's July 2026 Guidance

Preprint — analytical report. BHCL-PUB-2026-09-01, version 3.0, 15 September 2026. Not peer reviewed. Developmental-support software can influence assessment and intervention without making a diagnosis. Its regulation therefore requires a precise intended purpose, proportionate evidence, and control of software changes. This analytical report examines the April 2026 Indian licensing of PinnacleAI GPT-OS v1.0.0 and retrospectively assesses the case against CDSCO’s medical-device-software guidance released in July 2026. Electronic copies of the issued manufacturing licence, its accompanying letter, and quality-system certificates were examined alongside the manufacturer’s case account and public regulatory sources. Digital signatures and current registry status were not independently validated. The MD-5 licence and matching covering letter establish the documented Class B scope, an application dated 16 April, and a grant dated 21 April 2026. The manufacturer separately reports a classification decision on 13 April and a notified-body audit on 18 April. The comparison identifies continuity with the July guidance while distinguishing a software release record from a test licence, a management-system licence from product-performance certification, and risk classification from clinical validity. A claim–evidence matrix shows how licensing, technical verification, clinical evaluation, and outcome studies answer different questions. The case contributes a reusable documentary framework for developmental-support software regulation. Its findings concern a documented regulatory pathway and evidence architecture; they do not establish comparative effectiveness, international authorisation, or a general licensing timetable. Files comprise the manuscript in PDF and editable Word, with supplementary publication figures and captions. Commercial interests and source-verification limitations are disclosed in the manuscript.

Authors

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-09-15
DOI
https://doi.org/10.5281/zenodo.22761781
Primary Topic
Biomedical Ethics and Regulation
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
preprint

Licensing Developmental-Support Software in India: An April 2026 Case Study Assessed Against CDSCO's July 2026 Guidance

Koti Reddy Saripalli
Zenodo (CERN European Organization for Nuclear Research)
Biomedical Ethics and Regulation
preprint

Licensing Developmental-Support Software in India: An April 2026 Case Study Assessed Against CDSCO's July 2026 Guidance

Koti Reddy Saripalli
preprint en

Abstract

Preprint — analytical report. BHCL-PUB-2026-09-01, version 3.0, 15 September 2026. Not peer reviewed. Developmental-support software can influence assessment and intervention without making a diagnosis. Its regulation therefore requires a precise intended purpose, proportionate evidence, and control of software changes. This analytical report examines the April 2026 Indian licensing of PinnacleAI GPT-OS v1.0.0 and retrospectively assesses the case against CDSCO’s medical-device-software guidance released in July 2026. Electronic copies of the issued manufacturing licence, its accompanying letter, and quality-system certificates were examined alongside the manufacturer’s case account and public regulatory sources. Digital signatures and current registry status were not independently validated. The MD-5 licence and matching covering letter establish the documented Class B scope, an application dated 16 April, and a grant dated 21 April 2026. The manufacturer separately reports a classification decision on 13 April and a notified-body audit on 18 April. The comparison identifies continuity with the July guidance while distinguishing a software release record from a test licence, a management-system licence from product-performance certification, and risk classification from clinical validity. A claim–evidence matrix shows how licensing, technical verification, clinical evaluation, and outcome studies answer different questions. The case contributes a reusable documentary framework for developmental-support software regulation. Its findings concern a documented regulatory pathway and evidence architecture; they do not establish comparative effectiveness, international authorisation, or a general licensing timetable. Files comprise the manuscript in PDF and editable Word, with supplementary publication figures and captions. Commercial interests and source-verification limitations are disclosed in the manuscript.

Zenodo (CERN European Organization for Nuclear Research)
Pinnacle Clinical Research (US)
Partnerships for the goals
Biomedical Ethics and Regulation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Licensing Developmental-Support Software in India: An April 2026 Case Study Assessed Against CDSCO's July 2026 Guidance — Koti Reddy Saripalli · Zenodo (CERN European Organization for Nuclear Research) (2026) | TGRS Research Map | TGRS